# A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

> **NCT01454089** · PHASE2 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 183 (actual)

## Conditions studied

- Urologic Neoplasms
- Metastatic Bladder Cancer
- Urinary Tract Neoplasms

## Interventions

- **DRUG:** OGX-427 600 mg
- **DRUG:** OGX-427 1000 mg
- **DRUG:** Placebo
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01454089
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2016-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454089, "A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01454089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*